Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease

Rhea-AI Summary

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will host a webcast and conference call on June 8, 2022, at 8:00 a.m. ET to discuss top-line results from its Phase 3 TRANQUILITY-2 Trial of reproxalap in treating dry eye disease. Interested participants can access the call via dial-in numbers or through a live audio webcast on Aldeyra's website. Following the event, a recording will be available on the site for 90 days. Aldeyra is focused on innovative therapies targeting immune-mediated diseases.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Wednesday, June 8, 2022, at 8:00 a.m. (ET) to provide top-line results from the Phase 3 TRANQUILITY-2 Trial of reproxalap in dry eye disease.

The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 879247. A live audio webcast of the conference call also will be accessible from the “Investors & Media” section of Aldeyra's website at ir.aldeyra.com.

After the live webcast, the event will remain archived on Aldeyra’s website for 90 days.

About Aldeyra

Aldeyra develops innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220607006078/en/

Investors & Media:

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: (857) 383-2409

ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.

FAQ

What is the purpose of the TRANQUILITY-2 Trial?

The TRANQUILITY-2 Trial aims to evaluate the efficacy of reproxalap in treating dry eye disease.

When will Aldeyra announce the results of the TRANQUILITY-2 Trial?

Aldeyra will announce the results of the TRANQUILITY-2 Trial during the webcast and conference call on June 8, 2022.

How can I access the Aldeyra conference call?

You can access the conference call by dialing (844) 200-6205 for domestic callers or (929) 526-1599 for international callers, using access code 879247.

Where can I find the archived webcast after the live event?

The archived webcast will be available on Aldeyra's website for 90 days following the event.

What is reproxalap used for?

Reproxalap is being developed to treat dry eye disease and allergic conjunctivitis.